Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds

Core Insights - The study published in the Journal of Medical Economics highlights the cost savings and improved health outcomes associated with CellerateRX® when used as an adjunct to standard care for high-risk spinal surgery patients [1][2]. Economic and Clinical Evaluation - Researchers utilized economic modeling to assess clinical outcomes and direct medical costs for high-comorbidity patients undergoing complex spinal surgeries, comparing two treatment groups: one receiving CellerateRX and the other receiving standard care alone [2][3]. - The study measured postoperative complications, hospital readmissions, and surgical revisions over a one-year period, with clinical efficacy evaluated in quality-adjusted life years (QALYs) and costs in 2025 U.S. dollars [3]. Cost-Effectiveness Findings - The CellerateRX treatment group demonstrated a cost savings of $3,852 per patient and a QALY gain of 0.007, resulting in a net monetary benefit of $4,542 [4]. - Major contributors to cost savings included avoidance of hospital readmissions ($2,238) and surgical revisions ($835) [4]. - In probabilistic analyses, CellerateRX showed a dominant cost-effectiveness profile in over 99% of clinical variability simulations compared to standard care [4]. Conclusion and Implications - The findings support CellerateRX as a value-enhancing component in the management of surgical wounds for high-risk spinal surgery patients, promoting both improved health outcomes and cost savings [5].